Odunsi et al. demonstrated that treatment with PBMCs and anti-PD-1 antibodies, or TALs and anti-PD-1 antibodies slowed tumor growth rate, however, dual anti-PD1/anti-CTLA4 treatment significantly reduces ovarian cancer growth comparing to control. The gene discussed is CTLA4; the disease is neoplasm.